SR-717 is primarily investigated for its role as a selective agonist of the STING (Stimulator of Interferon Genes) pathway, making it a key compound in immunotherapy research. It activates the innate immune system by inducing the production of type I interferons and pro-inflammatory cytokines, which enhances the body’s ability to detect and eliminate tumor cells. This property is being explored in cancer treatment, particularly in solid tumors, where intratumoral injection of SR-717 has shown potential to shrink tumors and promote systemic anti-tumor immunity. Additionally, its stability and ability to bind effectively to various STING variants make it a promising candidate for vaccine adjuvants and antiviral therapies. Research is ongoing to optimize delivery methods and evaluate its efficacy in combination with other immunotherapies.